SCNI

Business Context and Reporting Period

Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 8, 2024
Context: The filing serves to notify shareholders and the SEC of an upcoming Extraordinary Meeting of Shareholders scheduled for August 12, 2024. The document includes the Notice and Proxy Statement and a Proxy Card for American Depositary Shareholders.

Financial Metrics

This filing is a corporate governance notification and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No material financial changes or operational updates are reported in this document. The filing focuses solely on the procedural details of the shareholder meeting.

Guidance, Outlook, and Risks

Management Commentary: The Company is convening an Extraordinary Meeting to vote on specific proposals detailed in the attached Notice and Proxy Statement (Exhibit 99.1).
Meeting Details:

• Date: Monday, August 12, 2024
• Time: 11:00 a.m. Israel time
• Location: Offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv, Israel

Risks and Contingencies: No specific risks or contingencies are disclosed in this summary text; investors are directed to the full Proxy Statement for details on proposals and voting procedures.

Key Facts for Investor Verification

• Verify the specific proposals to be voted upon in the attached Notice and Proxy Statement (Exhibit 99.1).
• Confirm the record date for shareholder eligibility, which is not stated in this summary but is contained in the full Proxy Statement.
• Review the voting procedures for American Depositary Shareholders via the Proxy Card (Exhibit 99.2).
• Note that this filing incorporates by reference into the Company's Registration Statements on Form S-8 and Form F-3.